Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04224493 |
|
Recruitment Status :
Recruiting
First Posted : January 13, 2020
Last Update Posted : May 8, 2024
|
Sponsor:
Epizyme, Inc.
Information provided by (Responsible Party):
Ipsen ( Epizyme, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | September 30, 2029 |
| Estimated Study Completion Date : | April 27, 2032 |